Don't test -- don't treat: the new paradigm for the treatment of prostate cancer?
作者信息
Albani Justin M
机构信息
Urology Specialists, PC, in North Kansas City, USA.
出版信息
Mo Med. 2011 Nov-Dec;108(6):409-12.
Abstract
摘要
相似文献
1
Don't test -- don't treat: the new paradigm for the treatment of prostate cancer?不检测——不治疗：前列腺癌治疗的新范式？
Mo Med. 2011 Nov-Dec;108(6):409-12.
2
Prostate cancer screening: what we know, don't know, and believe.前列腺癌筛查：我们所知道的、不知道的以及所相信的。
Ann Intern Med. 2012 Jul 17;157(2):135-6. doi: 10.7326/0003-4819-157-2-201207170-00460.
3
New PSA guidelines discourage overscreening.新的前列腺特异性抗原（PSA）指南不鼓励过度筛查。
J Natl Cancer Inst. 2012 Jan 4;104(1):8-9. doi: 10.1093/jnci/djr539. Epub 2011 Dec 14.
4
Prostate cancer: Prudent practice optimizes screening outcomes.前列腺癌：审慎的做法可优化筛查结果。
Nat Rev Urol. 2016 Jul;13(7):376-7. doi: 10.1038/nrurol.2016.90. Epub 2016 May 24.
5
Summaries for patients. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians.患者摘要。前列腺癌筛查：美国医师协会临床指南委员会的一份指导声明。
Ann Intern Med. 2013 May 21;158(10):I-28. doi: 10.7326/0003-4819-158-10-201305210-00634.
6
[Analysis of recommendations against prostate cancer screening with prostate specific antigen].[关于反对使用前列腺特异性抗原进行前列腺癌筛查的建议分析]
Med Clin (Barc). 2016 Oct 21;147(8):361-365. doi: 10.1016/j.medcli.2016.03.002. Epub 2016 Apr 13.
7
[Recommendations against prostate cancer screening with PSA].[反对使用前列腺特异性抗原（PSA）进行前列腺癌筛查的建议]
Aten Primaria. 2012 Jul;44(7):377-8. doi: 10.1016/j.aprim.2012.02.005. Epub 2012 Apr 18.
8
I can not understand!我不明白！
Int Braz J Urol. 2012 May-Jun;38(3):296-7. doi: 10.1590/s1677-55382012000300001.
9
[Authorities in USA don't recommend screening for prostate cancer].美国当局不建议筛查前列腺癌。
Lakartidningen. 2011;108(46):2362.
10
Risks of PSA screening now better understood.前列腺特异性抗原（PSA）筛查的风险现在有了更深入的了解。
J Natl Cancer Inst. 2013 Nov 6;105(21):1590-2. doi: 10.1093/jnci/djt328. Epub 2013 Oct 18.
引用本文的文献
1
Abandoning PSA test is a deeply flawed recommendation.放弃前列腺特异性抗原（PSA）检测是一项存在严重缺陷的建议。
Mo Med. 2011 Nov-Dec;108(6):427.
本文引用的文献
1
Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force.前列腺癌筛查：美国预防服务工作组的证据回顾。
Ann Intern Med. 2011 Dec 6;155(11):762-71. doi: 10.7326/0003-4819-155-11-201112060-00375. Epub 2011 Oct 7.
2
Comorbidity and mortality results from a randomized prostate cancer screening trial.随机前列腺癌筛查试验的合并症和死亡率结果。
J Clin Oncol. 2011 Feb 1;29(4):355-61. doi: 10.1200/JCO.2010.30.5979. Epub 2010 Nov 1.
3
Cancer statistics, 2010.癌症统计数据，2010 年。
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7.
4
Mortality results from the Göteborg randomised population-based prostate-cancer screening trial.哥德堡随机人群前列腺癌筛查试验的死亡率结果。
Lancet Oncol. 2010 Aug;11(8):725-32. doi: 10.1016/S1470-2045(10)70146-7. Epub 2010 Jul 2.
5
Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.筛查和临床检出前列腺癌的前列腺癌死亡率：估计筛查的获益。
Eur J Cancer. 2010 Jan;46(2):377-83. doi: 10.1016/j.ejca.2009.09.008. Epub 2009 Oct 3.
6
Prostate specific antigen best practice statement: 2009 update.前列腺特异性抗原最佳实践声明：2009年更新版
J Urol. 2009 Nov;182(5):2232-41. doi: 10.1016/j.juro.2009.07.093. Epub 2009 Sep 24.
7
Screening and prostate-cancer mortality in a randomized European study.一项欧洲随机研究中的筛查与前列腺癌死亡率
N Engl J Med. 2009 Mar 26;360(13):1320-8. doi: 10.1056/NEJMoa0810084. Epub 2009 Mar 18.
8
Mortality results from a randomized prostate-cancer screening trial.一项前列腺癌随机筛查试验的死亡率结果。
N Engl J Med. 2009 Mar 26;360(13):1310-9. doi: 10.1056/NEJMoa0810696. Epub 2009 Mar 18.
9
Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.前列腺癌筛查：美国预防服务工作组建议声明
Ann Intern Med. 2008 Aug 5;149(3):185-91. doi: 10.7326/0003-4819-149-3-200808050-00008.
10
The triple aim: care, health, and cost.三重目标：医疗、健康和成本。
Health Aff (Millwood). 2008 May-Jun;27(3):759-69. doi: 10.1377/hlthaff.27.3.759.
Zotero 插件